« Return to News | Drug Sponsors

Codexis extends collaboration with Merck to 2015

Wednesday, May 23, 2012 09:50 AM

Redwood City, Calif.-based Codexis, a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals and pharmaceuticals, has extended its catalyst and process development collaboration with Merck to develop enzymes for use in pharmaceutical manufacturing for three more years.

As the collaboration enters its sixth year, Merck will continue to use Codexis’ proprietary enzyme products to develop more cost- and resource-efficient manufacturing processes for its pipeline of therapeutic candidates. The initial agreement was announced in April 2007 and the new agreement provides an extension to 2015.

Merck has evaluated the use of Codexis enzymes extensively across programs in various stages of development. In addition, the companies have collaborated to develop enzymes for custom reactions, most notably for sitagliptin, the active pharmaceutical ingredient in Merck’s Januvia.

“We are very pleased to continue this important relationship,” said Peter Strumph, interim CEO, Codexis. “Our collaboration with Merck has led to a number of breakthroughs in pharmaceutical manufacturing that have been adopted by Merck in some of their leading pharmaceutical products. We look forward to continuing to develop additional cost-advantaged manufacturing processes with Merck.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.